Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personal Experience with MDMA, LSD, and Psilocybin in Substance-assisted Therapy Training
NCT05570708Enrolling by invitation
- Start
- Oct 2022
- Primary completion
- Jun 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of midomafetamine, Lysergide and psilocybin. Primary endpoint: Therapeutic Attitude Scales-Revised. Started Oct 2022; status: enrolling by invitation.
02
Drugs
midomafetamineLysergidepsilocybin
Beyond the preview
Go deeper on NCT05570708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570708.